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LAY ABSTRACT
This study reviewed data from 50 chronic stroke patients 
with spastic equinovarus foot in order to compare the 
outcome of tibial nerve (main trunk and motor branches) 
diagnostic block (which temporarily relieves focal mus-
cle overactivity, allowing assessment of the contribution 
of different muscles) with that of subsequent botulinum 
toxin injected into the same muscles as were targeted 
by the nerve block. Outcome measures were passive 
motility of the affected ankle and overactivity of the calf 
muscles. All patients were evaluated before and after 
the nerve block, and 4 weeks after the botulinum toxin 
injection. Significant improvements were found both af-
ter the nerve block and after botulinum toxin injection in 
comparison with the baseline condition; however, the im-
provements observed after nerve block were significantly 
greater. These results confirm that diagnostic nerve block 
is a useful screening tool for use before botulinum toxin 
treat ment, although less improvement occurred after bo-
tulinum toxin injection compared with after nerve block.
Objective: To evaluate the role of diagnostic nerve 
block in predicting the outcome of subsequent botu-
linum toxin type A treatment for spastic equinovarus 
foot due to chronic stroke.
Design: Retrospective observational study.
Patients: Fifty chronic stroke patients with spastic 
equinovarus foot.
Methods: Each patient was given diagnostic tibial 
nerve block (lidocaine 2% perineural injection) as-
sessment followed by botulinum toxin type A ino-
culation into the same muscles as had been targe-
ted by the nerve block. All patients were evaluated 
before diagnostic nerve block, after the nerve block, 
and 4 weeks after botulinum toxin injection. Outco-
mes were ankle dorsiflexion passive range of mo-
tion of the affected side, and calf muscle spasticity, 
measured with the modified Ashworth scale and the 
Tardieu Scale. 
Results: Significant improvements were measured 
after diagnostic nerve block and botulinum toxin 
injection compared with the baseline condition. Di-
agnostic nerve block led to significantly greater im-
provements in all outcomes than botulinum toxin 
injection.
Conclusion: This study confirmed diagnostic ner-
ve block as a valuable screening tool in deciding 
whether to treat spastic equinovarus with botulinum 
toxin. However, the results support the evidence that 
diagnostic nerve block results in a greater reduction 
in muscle overactivity than does botulinum toxin type 
A in patients with spastic equinovarus due to stroke.
Key words: botulinum toxin; diagnosis; equinus deformity; 
muscle spasticity; nerve block.
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Botulinum toxin type A (BoNT-A) is an effective and safe first-line treatment for lower limb spastic 
muscle overactivity post-stroke (1). Spastic equino-
varus foot is the pattern most commonly treated with 
BoNT-A in patients with lower limb spastic muscle 
overactivity (2). Spastic equinovarus foot after stroke 
has the following main causes: calf muscle spasticity; 
spastic calf muscle contracture/shortening; ankle dor-
siflexor muscle weakness leading to drop-foot during 
the swing phase of gait; imbalance between the tibialis 
anterior and peroneus muscles (3). 
Diagnostic nerve block (DNB) transiently relieves 
focal muscle hypertonia (4). It allows the differentiation 
of spastic muscle overactivity from contracture, deter-
mination of the respective role of different muscles in 
patterns of overactivity, and testing of the strength of 
antagonist muscles (3–5). Thus, DNB of the tibial nerve 
and its motor branches is recommended to determine 
the causes of spastic equinovarus foot and define its 
most appropriate therapeutic management (3). 
Treatment with BoNT-A is indicated in patients with 
a notable/complete correction of spastic equinovarus 
foot in the swing and stance phases of gait after tibial 
nerve (main trunk and motor branches) DNB (3). 
However, from a clinical point of view, even though 
selective DNB of the tibial nerve motor branches re-
presents a key way to identify which muscles to inject 
with BoNT-A, it may be challenging to replicate the 
outcome of DNB by means of BoNT-A injection (6). 
This must be considered together with the major causes 
of loss of BoNT-A response in patients with spastic 
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muscle overactivity (i.e. inaccurate selection and 
identification of the correct muscle for injection, insuf-
ficient drug dosage, inadequate injection technique, 
development of changes in the muscle, and formation 
of neutralizing antibodies) (7).
Although DNB is suggested to predict the effects of 
treatment for muscle hypertonia by simulating its out-
come (3, 4), to the best of our knowledge no previous 
study has compared the effects of DNB and BoNT-A 
injection. Conversely, this issue has been investigated 
previously by Deltombe and colleagues with regard to 
selective tibial neurotomy (8). This permanent neuro-
surgical procedure showed equal efficacy to DNB of 
the tibial nerve for treating spastic equinovarus foot 
in hemiplegic patients (8). Thus, DNB has been sug-
gested as a valuable screening tool prior to neurotomy. 
The main aim of this study was to evaluate the role of 
DNB in predicting the outcome of BoNT-A treatment 
for spastic equinovarus foot due to chronic stroke. 
METHODS
This single-centre, retrospective (chart review), observational 
study analysed data from 50 chronic stroke patients with spastic 
equinovarus foot, who had undergone BoNT-A injection into 
the spastic calf muscles after tibial nerve DNB at our clinical 
Neurorehabilitation Unit, from January 2016 to December 2019. 
Inclusion criteria were: age over 18 years; spastic equinovarus 
foot consequent to first-ever unilateral ischaemic or haemorrhagic 
stroke (documented by a computerized tomography scan or mag-
netic resonance imaging; subarachnoid haemorrhage excluded); 
calf muscles spasticity graded at least 2 on the Modified Ashworth 
Scale (MAS) (9); at least 6 months since stroke onset; notable/
complete relief of spastic equinovarus foot after tibial nerve (mo-
tor branches and main trunk) DNB; spasticity pattern involving 
at least one of the following muscles: soleus, tibialis posterior, 
gastrocnemius medialis and gastrocnemius lateralis (10). 
Exclusion criteria were: participation in other trials; spasticity 
pattern involving the following muscles: flexor digitorum longus, 
flexor digitorum brevis, flexor hallucis longus and extensor 
hallucis longus (10); previous treatment of spastic equinovarus 
foot with neurolytic or surgical procedures; other neurological 
or orthopaedic conditions involving the affected lower limb. 
All participants were outpatients. All patients provided infor-
med consent for data extraction from chart review, as needed. The 
study was carried out according to the principles of the Declara-
tion of Helsinki and was approved by the local Review Board.
Treatment procedures
According to our clinical practice, the affected leg of all patients 
was evaluated by serial selective DNB of tibial nerve motor 
branches (the DNB was performed first at the soleus motor 
nerve branch followed, in the case of no or scant relief of muscle 
overactivity, by the motor nerve branch to the tibialis posterior, 
to the gastrocnemius medialis and to the gastrocnemius lateralis 
muscles). If necessary, the DNB was finally performed at the 
tibial nerve main trunk (mixed sensorimotor nerve block) (8). 
Patients lay in the prone position with their legs outstretched 
during the whole procedure. A 22-gauge, 80-mm, ultrasound 
faceted tip echogenic needle for nerve block (SonoPlex STIM, 
Pajunk, Geisingen, Germany) was guided to the tibial nerve 
(motor branches and main trunk) by means of ultrasonography 
(MyLab 70 XVision, Esaote, Genoa, Italy) and electrical nerve 
stimulation (Plexygon ,Vygon, Padua, Italy). Anatomical land-
marks were used for linear transducer (scanning frequency 15 
MHz) and needle tip positions (11). Once tibial nerve (motor 
branches or main trunk) was identified by means of ultrasono-
graphy, following elicitation of appropriate muscular response 
to a 1 Hz, 100 μs, 0.5 mA electrical stimulus, lidocaine 2% was 
injected (1–2 ml for each motor nerve branch blockade and 5–6 
mL to block the main nerve trunk; no more than 10 mL in total 
per session). Gentle aspiration was performed before lidocaine 
injection to ensure the absence of vessels at the needle tip.
Once the spastic equinovarus pattern had been defined by tibial 
nerve (motor branches and main trunk) DNB, each patient was 
given ultrasound-guided BoNT-A inoculation into the spastic calf 
muscles. Only the muscles targeted for injection by DNB were 
treated (namely soleus and/or tibialis posterior and/or gastrocne-
mius medialis and/or gastrocnemius lateralis; see inclusion/exclu-
sion criteria) (12). Thus, BoNT-A treatment was tailored to each 
patient on the basis of DNB outcome. BoNT-A treatment features 
(injected muscles, toxin brand, dose, dilution, injection sites) were 
defined for each patient according to our daily clinical practice, 
which is line with the local regulatory and European guidelines 
(7). Our chart did not record information about the prescription 
or execution of adjuvant treatment (e.g. electrical stimulation, 
casting, taping or physiotherapy) in the period between BoNT-A 
treatment and after injection evaluation with DNB (13).
Evaluation procedures
All patients were evaluated before DNB, after DNB, and 4 weeks 
after BoNT-A treatment. Patients remained in the supine position 
with their knees extended during evaluations. The spastic ankle 
dorsiflexion passive range of motion (PROM) was measured 
using a handheld goniometer. The sensitivity of the measurement 
was set at 5°. The dorsiflexion angle was defined as positive and 
the plantar flexion angle as negative, taking 0° as the neutral 
position of the joint (14). The MAS is a 6-point scale grading 
the resistance of a relaxed limb to rapid passive stretch (0=no 
increase in muscle tone; 1 = slight increase in muscle tone at the 
end of the range of motion; 1+ = slight increase in muscle tone 
through less than half of the range of motion; 2 = more marked 
increase in muscle tone through most of the range of motion; 
3 = considerable increase in muscle tone; 4 = joint is rigid) (9). 
For statistical purposes, a score of 1 was considered as 1, a score 
of 1+ was considered as 2 and so on, up to a score of 4, which 
was considered as 5. The MAS was used to evaluate spastic calf 
muscles tone. The Tardieu Scale was used to evaluate spastic 
calf muscle tone according to the Tardieu Scale spasticity grade, 
which measured the gain in muscle reaction to fast stretch in dor-
siflexion from (0: no resistance throughout passive movement; 1: 
slight resistance throughout passive movement; 2: clear catch at 
a precise angle, interruption of the passive movement, followed 
by release; 3: fatigable clonus occurring at a precise angle; 4: 
unfatigable clonus occurring at a precise angle), and the Tardieu 
Scale spasticity angle, which measured the difference (a – b) 
between the angle of catch-and release/clonus at fast stretch in 
(b) dorsiflexion and (a) ankle dorsiflexion PROM (15).
Statistical analysis
Statistical analysis was performed with the Statistical Package 
for Social Science for Macintosh, version 26.0 (SPSS Inc., 
Armonk, NY, USA). Descriptive statistics were used for demo-
graphic and clinical features of our sample. The paired sample 
www.medicaljournals.se/jrm
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t-test was performed to compare the outcome of DNB and 
BoNT-A treatment with the baseline (before DNB evaluation). 
The alpha level for significance was set at p < 0.05. Bonferroni 
correction for multiple comparisons was applied, resulting in 
p < 0.016 as the significance threshold.
RESULTS
Demographic and clinical features of patients are 
reported in Table I.
Comparison of pre-DNB vs post-DNB conditions re-
vealed significant improvements after DNB in ankle 
PROM (t
49
 = –10.128; p < 0.001) and calf muscle spasti-
city on the MAS (t
49
 = 11.523; p < 0.001), Tardieu Scale 
spasticity grade (t
49
 = 7.849; p < 0.001) and Tardieu Sca-
le spasticity angle (t
49
 = 6.325; p < 0.001). Comparison 
of pre-DNB vs post-BoNT-A injection conditions sho-
wed significant improvements after BoNT-A injection 
in ankle PROM (t
49
 = –3.665; p = 0.001) and calf muscle 
spasticity on the MAS (t
49
 = 6.654; p < 0.001), Tardieu 
Scale spasticity grade de (t
49
 = 7.134; p < 0.001) and 
Tardieu Scale spasticity angle (t
49
 = 3.317; p = 0.008). 
Comparison of post-DNB vs post-BoNT-A injection 
conditions showed significant differences in favour of 
the post-DNB condition with regard to ankle PROM 
(t
49
 = 6.157; p < 0.001) and calf muscle spasticity 
on the MAS (t
49
 = –4.810; p < 0.001), Tardieu Scale 
spasticity grade (t
49
 = –3.383; p = 0.001) and Tardieu 
Scale spasticity angle (t
49
 = –3.960; p = 0.002). Table II 
shows the clinical features of the patients with spastic 
equinovarus foot and the results of the comparisons. 
DISCUSSION
Selective DNB of the tibial nerve and its motor bran-
ches is mandatory in order to evaluate and define the 
management of spastic equinovarus foot due to stroke 
(3, 6, 8, 16). The effectiveness of DNB indicates mus-
cle overactivity as the “main problem”, supporting the 
use of a drug treatment (such as BoNT-A) and helping 
the detection of muscles to inject (6). Our findings are 
in line with this view. Indeed, we observed that BoNT-
A injection into those muscles targeted by DNB of the 
tibial nerve (motor branches and main trunk) led to a 
significant improvement in spastic equinovarus foot 
by 4 weeks after treatment. Hence, this study further 
confirmed tibial nerve DNB as a valuable screening 
tool in decisions about treating spastic equinovarus foot 
with BoNT-A. Interestingly, both DNB and BoNT-A 
improved all outcomes (ankle PROM and calf muscle 
tone), which assessed both neural and non-neural com-
ponents of spastic muscle overactivity. Although our 
patients with stroke were long-term chronic patients 
(mean time from onset 6.5 years), this study only in-
cluded people with notable/complete relief of spastic 
Table I. Demographic and clinical features of patients
Characteristics
Age, years, mean (SD) 53.2 (16.4)
Sex, male/female, n 38/12
Time since stroke onset, months, mean (SD) 79.1 (68.7)
Stroke aetiology, ischaemic/haemorrhagic, n 34/16
Affected side, right/left, n 27/23
Walking ability, n
  Independent (FAC = 5)/dependent (FAC < 5) 18/32
BoNT-A treatments per muscle, n
  Gastrocnemius medialis 18
  Gastrocnemius lateralis 16
  Soleus 42
  Tibialis posterior 25
BoNT-A preparations injected, n
  AbobotulinumtoxinA 34
  IncobotulinumtoxinA 4
  OnabotulinumtoxinA 12
BoNT-A dose per patient, U, mean (SD)
  AbobotulinumtoxinA 472 (185)
  IncobotulinumtoxinA 263 (48)
  OnabotulinumtoxinA 219 (118)
Gastrocnemius medialis, U, BoNT-A dose, mean (SD)
  AbobotulinumtoxinA 188  (71)
  IncobotulinumtoxinA 63 (14)
  OnabotulinumtoxinA 83 (18)
Gastrocnemius lateralis, U, BoNT-A dose, mean (SD)
  AbobotulinumtoxinA 187 (65)
  IncobotulinumtoxinA 63 (14)
  OnabotulinumtoxinA 79 (11)
Soleus, U, BoNT-A dose, mean (SD)
  AbobotulinumtoxinA 313 (59)
  IncobotulinumtoxinA 119 (24)
  OnabotulinumtoxinA 98 (22)
Tibialis posterior, U, BoNT-A dose, mean (SD)
  AbobotulinumtoxinA 191 (50)
  IncobotulinumtoxinA 100 (7)
  OnabotulinumtoxinA 63 (18)
SD: standard deviation; n: number; FAC: Functional Ambulation Category; 
BoNT-A, botulinum toxin type A; U: units. 
Table II. Clinical features of spastic equinovarus foot and comparisons
Before DNB After DNB
After BoNT-A 
Injection
Comparisons
Before DNB vs post DNB
p-value (95% CI)
Before DNB vs post BoNT-A
p-value (95% CI)
Post DNB vs post BoNT-A
p-value (95% CI)
Ankle dorsiflexion 
PROM, mean (SD) –1.20 (8.12) 7.8 (7.4) 1.6 (7.6) <0.001 (–10.8 to –7.2)* 0.001 (–4.7 to –1.4)* <0.001 (4.2 to 8.3)*
MAS, median (IQR) 3.0 (3.0 to 4.0) 1.0 (1.0 to 2.0) 3.0 (1.0 to 3.0) <0.001 (1.4 to 2.0)* <0.001 (0.6 to 1.2)* <0.001 (–1.1 to –0.5)*
Tardieu Scale spasticity 
grade, median (IQR) 2.0 (2.0 to 3.0) 1.0 (0.8 to 2.0) 2.0 (1.0 to 2.0) <0.001 (1.1 to 1.8)* <0.001(0.6 to 1.1)* 0.001 (–0.9 to –0.1)*
Tardieu Scale spasticity 
angle, mean (SD) 13.5 (7.3) 2.9 (3.9) 11.5 (8.2) <0.001 (6.7 to 13.3)* 0.008 (1.6 to 8.3)* 0.002 (–14.9 to –4.3)*
*Significant correlation (p < 0.016). 
DNB: diagnostic nerve block; BoNT-A: botulinum toxin type A; CI: confidence interval; PROM: passive range of motion; MAS: Modified Ashworth Scale; SD: 
standard deviation; IQR: interquartile range.
J Rehabil Med 52, 2020
JR
M
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
A. Picelli et al.p. 4 of 5
equinovarus foot after tibial nerve (motor branches 
and main trunk) blockade. Hence, our patients had 
no clinically relevant contracture. On this basis, our 
findings are in line with the current literature, which 
reported improvements in passive joint motion and 
muscle tone after BoNT-A administration in patients 
with spastic muscle overactivity due to stroke (1, 17). 
Nonetheless, our personal experience suggested that 
it is not easy to obtain a similar outcome after DNB 
and BoNT-A injection. This is the main reason for this 
retrospective study, which aimed to evaluate whether 
the outcome of BoNT-A treatment might be predicted 
by tibial nerve DNB in chronic stroke patients with 
spastic equinovarus foot. The current findings showed 
that DNB led to a significantly greater reduction in 
muscle overactivity than BoNT-A treatment. Thus, 
our clinical impression about the challenge to replicate 
DNB outcome with BoNT-A injection is confirmed. 
Therapeutic management of spastic equinovarus foot 
may include focal treatment with drugs (BoNT-A injec-
tion and neurolysis with phenol or alcohol), rehabilita-
tion procedures (physiotherapy, muscle strengthening 
and stretching, taping, casting, orthosis, functional 
electrical stimulation, physical modalities) and surgical 
approaches (selective neurotomy, tendon transfer and 
tendon lengthening) (3, 13). Our clinical experience in 
this field is in line with the Mont-Godinne interdiscipli-
nary guidance, which considers the DNB of tibial nerve 
(main nerve trunk and motor branches) as the central 
point of a pathway for assessing and planning the ma-
nagement of spastic equinovarus foot in patients with 
stroke (3). Neural blockade with anaesthetics is a safe, 
low-cost, simple diagnostic tool to obtain a fast (few 
minutes) suppression of muscle overactivity, which 
may last for several hours depending on the anaesthe-
tics used (e.g. lidocaine 2% or bupivacaine 0.5%) (2, 3, 
8). Regarding stroke patients with spastic equinovarus 
foot, DNB and selective neurotomy (surgical partial 
section of selected motor nerve branches) were found 
equally to reduce muscle overactivity as a consequence 
of their similar action upon Ia fibres (which mediate the 
myotatic reflex) and alpha motor fibres (which mediate 
voluntary contraction) (8). On the other hand, despite 
the fact that BoNT-A is the focal treatment for muscle 
hypertonia with the highest level of evidence (level A), 
it has been found inferior to selective neurotomy for 
reducing muscle overactivity in patients with spastic 
equinovarus foot (1, 16). Based on similar reasoning, 
we decided to compare the effects of DNB and BoNT-
A injection. The results of the current study showed 
a lower reduction in spastic muscle overactivity after 
BoNT-A injection (compared with DNB), taking into 
account some of the main causes of non-response 
(i.e. DNB allowed us to correctly define the pattern of 
muscle overactivity and excluded clinically relevant 
contracture, and BoNT-A was properly injected into 
the overactive muscles by means of ultrasound) and 
according to the international consensus (7). On the 
other hand, despite the dosage of BoNT-A was defined 
according to the local regulatory, one may argue that 
it was insufficient to reach the same effect of DNB. 
This may be considered as a limitation of this study. 
Current evidence from the literature suggests that doses 
of BoNT-A higher than labelled ones are effective in 
reducing spasticity of the upper and lower limbs after 
stroke. Furthermore high doses of BoNT-A appear 
to be safe, with low occurrence of mild adverse ef-
fects (18, 19). However, to date, the administration of 
high-dose BoNT-A has been debated mainly in terms 
of maximum dose per treatment session in order to 
allow the injection of a larger number of muscles (18, 
19) in multilevel treatments. Less is known about the 
maximum dose per muscle in relation to the total body 
dose. Future research should improve our knowledge 
about this issue. Other limitations of this study are as 
follows. First, we did not include a control group to 
assess the importance of muscle targeting by means of 
DNB for the success of BoNT-A injection into the pos-
terior calf muscles. Secondly, the design of this study 
was retrospective, thus there was no standardization 
of our patients before and after interventions. Thirdly, 
our patients were evaluated at one month after a single 
BoNT-A treatment. Thus, we cannot draw conclusions 
about the clinical condition of our patients later in 
the same injection cycle or about how many BoNT-A 
injection cycles are needed to obtain improvements 
similar to those observed after DNB. Fourthly, we did 
not consider an outcome measure more related to spas-
tic co-contraction and active function, such as ankle 
dorsiflexion active range of motion. Fifthly, even if our 
charts did not report the prescription or execution of 
adjuvant treatments after BoNT-A injection, conside-
ring the retrospective design of this study, we cannot 
be sure about the activities performed by our patients 
after BoNT-A injection. Moreover, we cannot infer 
about the add-on effect of adjuvant therapies to gain 
improvement similar to DNB after BoNT-A treatment 
(13). Sixthly, no functional (e.g. motion analysis) and 
neurophysiological (e.g. electromyography) evaluation 
was performed to assess improvements after DNB and 
BoNT-A injection.
In conclusion, this study confirmed DNB as a valua-
ble screening tool in making decisions about treating 
spastic equinovarus foot with BoNT-A. However, 
the results support the evidence that DNB allows a 
greater reduction in muscle overactivity than BoNT-A 
in patients with spastic equinovarus due to stroke. To 
improve these observations, larger scale prospective 
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studies are needed, taking into account (and overco-
ming) the limitations reported above.
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